Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

NCT ID: NCT05954858

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-29
• Study Completion Date: 2027-06-30

Brief Summary

This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients.

The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).

Detailed Description

Glioblastoma (GBM) is the most common primary central nervous system malignancy in adults, and accounts for over half of all malignant brain tumors. The prognosis for newly diagnosed GBM is extremely poor even with Stupp protocol consisting of surgery followed by temozolomide and radiotherapy. For newly diagnosed GBM the median overall survival (OS) is only 15 months, and the median progression-free survival (PFS) is a mere 5-6 months with only 53.9% of patients having 6 month PFS.

This Phase 2 study is an extension of our recently completely enrolled Phase I trial which showed the initial safety of a TPF into the resection cavity of newly diagnosed GBM. All 36 subjects included in this Phase 2 study will initially undergo standard surgical resection for newly diagnosed GBM. Following the resection, the surgical cavity will be lined with a long pedicled, autologous piece of tissue called a temporoparietal fascial flap or pericranium. The patient's dura, bone and scalp will be closed as is customary. The subject will be followed for side effects at 72 hours, 7 days, 30 days, 60 days, 120 days and 180 days. The primary outcome measure will be progression free survival (PFS) and secondary outcome measures will include overall survival (OS). Risk assessment will include seizure, stroke, infection, tumor progression, and death.

Conditions

Glioma, Malignant; Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme, Adult; High Grade Glioma; GBM; Brain Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Surgical tissue autograft: TPF flap/pericranial flap

Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients

Group Type: EXPERIMENTAL

Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)

Intervention Type: PROCEDURE

Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.

Interventions

Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)

Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.

Intervention Type: PROCEDURE

Other Intervention Names

surgical tissue flap; tissue autograft

Eligibility Criteria

Inclusion Criteria

1. Subject is a male or female 18 years of age or older.

2. Subject is undergoing planned resection of known or suspected GBM.

3. Subject has a Karnofsky Performance Status (KPS) 70% or greater.

4. Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.

5. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region.

6. Subject must be able to undergo MRI evaluation.

7. Subject meets the following laboratory criteria:

1. White blood count ≥ 3,000/μL

2. Absolute neutrophil count ≥ 1,500/μL

3. Platelets ≥ 100,000/μL

4. Hemoglobin > 10.0 g/dL (transfusion and/or ESA allowed)

5. Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)

6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN

7. Blood urea nitrogen (BUN) and creatinine < 1.5 x ULN

8. Females of reproductive potential must have a negative serum pregnancy test and be willing to use an acceptable method of birth control.

9. Males of reproductive potential must be willing to use an acceptable method of birth control to ensure effective contraception with partner.

10. Able to understand and willing to sign an institutional review board (IRB)- approved written informed consent document (legally authorized representative permitted).

1. Subject has a histologically confirmed (frozen section) diagnosis of WHO Grade IV glioblastoma multiforme (GBM).

2. TPFF and/or pericranial flap is technically feasible.

Exclusion Criteria

1. Subject, if female, is pregnant or is breast feeding.

2. Subject has initiated chemotherapy or radiation treatment for diagnosis of or GBM.

3. Subject intends to participate in another clinical trial

4. Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.

5. Subject has an active infection requiring treatment.

6. Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.

7. Subject has a history of other malignancy, unless the patient has been disease- free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment

8. Subject has a known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection.

9. Subject has a history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Northwell Health

OTHER

Sponsor Role: lead

Responsible Party

John Boockvar, MD Zucker SOM @Hofstra/Northwell

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

John Boockvar, MD

Role: PRINCIPAL_INVESTIGATOR

Feinstein Institute for Medical Research/Lenox Hill Hospital

Locations

Lenox Hill Brain Tumor Center

New York, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

John Boockvar, MD

Role: CONTACT

jboockvar@northwell.edu

212-434-3900

Tamika Wong, MPH

Role: CONTACT

twong4@northwell.edu

212-434-4836

Facility Contacts

John Boockvar, MD

Role: primary

twong4@northwell.edu

212-434-3900

Tamika Wong, MPH

Role: backup

twong4@northwell.edu

212-434-4836

Other Identifiers

23-0385

Identifier Type: -

Identifier Source: org_study_id